Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance
(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
Pyruvate carboxylase (PC) ASO decreased hepatic DAG content and PKCε activation and increased hepatic Akt phosphorylation
in HFF rats. A: Hepatic DAG content (n = 9–10 per group). *P < 0.05 compared with control ASO group. B: PKCε activation. The average of control ASO group was set as 1 (n = 5 per group). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. $$P < 0.001 compared with control ASO group. C: Akt phosphorylation (Ser473). The average expression of control ASO group in the basal condition was set as 1 (n = 5 per group). #P < 0.05 and ###P < 0.001 compared with control ASO group in basal condition. **P < 0.01 compared with control ASO group in clamp condition. All tissues were taken at 4–5 weeks of treatment.